Novo Nordisk Finds Relief as Rival’s Production Woes and Buyback Bolster Recovery
Novo Nordisk shares have climbed more than 43% from their March nadir, riding a recovery that now draws…
Novo Nordisk Marches Beyond Obesity as Hemophilia Data and Buyback Bolster Confidence
Novo Nordisk’s B-shares closed at €43.32 on Friday, adding 1.29% as the stock continues its recovery from a…
Oral Wegovy Debut in Britain and Analyst Bids Bolster Novo Nordisk as Eli Lilly Tightens Grip on Key
Novo Nordisk has started selling an oral version of its blockbuster obesity drug Wegovy to private patients in…
Novo Nordisk Faces Two Realities: EU Approvals Bolster Pipeline as Canadian Patent Loss and Pricing
Novo Nordisk secures EU backing for oral and high-dose Wegovy but faces Canadian patent loss on Ozempic, triggering…
Novo Nordisk’s Pipeline Deepens as Amycretin and MASH Data Bolster a Stretched Stock
Novo Nordisk advances metabolic disease pipeline with Semaglutide success in MASH, high-dose Wegovy weight loss data, and Amycretin…